Bimagrumab
Anti-activin type II receptor antibody
Bimagrumab (Anti-activin type II receptor antibody) is a metabolic & fat loss research compound. A monoclonal antibody that blocks the activin type II receptor, preventing myostatin and activin from signaling. Blocking that pathway removes the brake on muscle growth — the result in trials is simultaneous fat loss and lean mass GAIN, which is close to unique and is exactly why it's being studied alongside GLP-1s, where muscle loss is the main criticism.
Bimagrumab quick facts
| Reported research dose | 10mg/kg every 4 weeks |
| Route | IV (trials) |
| Frequency | Monthly IV in trials |
| Half-life | Weeks (monoclonal antibody) |
| Forms | Other |
| Evidence level | Phase 2 human trials |
The most interesting thing in the body-composition space right now, and not available. It is an investigational biologic given intravenously in trials — not something in gray-market circulation, and anything sold under this name almost certainly isn't it. Watch the GLP-1 combination trials.
How Bimagrumab works
A monoclonal antibody that blocks the activin type II receptor, preventing myostatin and activin from signaling. Blocking that pathway removes the brake on muscle growth — the result in trials is simultaneous fat loss and lean mass GAIN, which is close to unique and is exactly why it's being studied alongside GLP-1s, where muscle loss is the main criticism.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Can you actually get Bimagrumab?
A discontinued Novartis investigational antibody. It was never approved, no pharmacy dispenses it, and no telehealth service can prescribe it. Here because the myostatin data is genuinely interesting — not because you can get it.
The evidence for Bimagrumab
Graded by what exists behind each claim.
✅ Clinically validated
- Reached phase 2 with a genuinely unusual result. A randomized trial in obese adults with type 2 diabetes reported roughly 20% loss of fat mass alongside a ~4% gain in lean mass over 48 weeks — body recomposition, not weight loss, and the scale weight barely moved.
- It failed its earlier target indications. A phase 2b/3 in sporadic inclusion body myositis missed its primary endpoint despite increasing muscle mass — a clean example of mass without function, which is the single most important caveat about this mechanism.
📊 Correlative data
- No marketed use; it was acquired by Eli Lilly and is being studied in combination with tirzepatide, on the logic that it addresses GLP-1's lean-mass problem.
- Trial adverse effects were mostly muscle cramps, diarrhea and acne. Long-term data does not exist.
🧪 Theoretical / extrapolated
- A monoclonal antibody blocking the activin type II receptor, which is the shared receptor for myostatin and the activins — the negative regulators of muscle mass. Block the receptor and you remove the brake.
- Blocking the receptor rather than one ligand is the design choice, and it is why the effect is larger than myostatin inhibition alone: several ligands converge there.
- The IBM failure is the mechanism's own warning. Removing a growth brake adds tissue; it does not guarantee that tissue is functional or well-innervated. And ActRII signaling does other things — the same pathway is involved in bone and reproductive biology.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Bimagrumab actually does
Bimagrumab is a monoclonal antibody that blocks a receptor rather than neutralizing a ligand, and that single design decision is why its effect is larger than every myostatin antibody that came before it.
The pathway. Myostatin, activin A and several related TGF-beta superfamily ligands do not each have their own receptor. They converge on the activin type II receptors, ActRIIA and ActRIIB, which then recruit a type I receptor (ALK4 or ALK5) and phosphorylate Smad2 and Smad3. The Smad complex enters the nucleus and represses the transcriptional program of muscle growth. It is a brake, held on continuously, by several ligands at once Rodgers 2022.
So blocking one ligand leaves the others pushing on the same pedal. That is the mechanistic reason the myostatin-antibody era produced modest muscle gains, and the reason a receptor blocker produces larger ones: it takes the whole convergence point out at once. It is also, precisely, the reason the safety questions are broader — the ligands being blocked have jobs outside skeletal muscle, in bone and in reproductive biology Rodgers 2022.
The metabolic half of the effect is the genuinely surprising part. Removing the brake adds muscle, which is expected. What was not expected is the size of the fat loss beside it: fat mass down 20.5% while lean mass rose 3.6% over 48 weeks Heymsfield 2021. Muscle is metabolically expensive tissue, and adding it while holding intake roughly constant changes the energy balance without changing appetite — which is a completely different route to the same scale reading than any incretin takes.
And the mechanism's most important warning is in its own trial history. Blocking a growth brake adds tissue. It does not guarantee the tissue is innervated, well-perfused or contractile, and the inclusion body myositis program is the published demonstration that mass and function can move independently Amato 2021. That is the fact to hold onto before reading any body composition number.
Cell, rodent, human — and where it stops
Step one, the phase 2 body composition trial, which is the result everyone quotes. 75 adults with type 2 diabetes, BMI 28 to 40 and HbA1c 6.5–10.0%, randomized to bimagrumab 10 mg/kg (up to 1200 mg) intravenously every 4 weeks or placebo for 48 weeks, both arms receiving diet and exercise counseling; 58 of 75 completed. Changes at week 48, bimagrumab against placebo: fat mass −20.5% (−7.5 kg) versus −0.5%; lean mass +3.6% (+1.70 kg) versus −0.8%; waist circumference −9.0 cm versus +0.5 cm; HbA1c −0.76 percentage points versus −0.04; body weight −6.5% (−5.9 kg) versus −0.8% Heymsfield 2021.
Step two, and this is the trial that should be quoted next to it and almost never is. In sporadic inclusion body myositis, 211 participants entered the extension of RESILIENT on 1, 3 or 10 mg/kg or placebo every 4 weeks. Mean change in 6-minute walk distance was highly variable and indicated progressive deterioration from weeks 24 to 104 in all treatment groups. The extension was terminated early because the core study did not meet its primary endpoint, and the authors' conclusion is that long-term treatment was safe and well tolerated and did not provide meaningful functional benefit Amato 2021.
Two years of a drug that reliably adds muscle mass, and the walking distance still fell. That is the cleanest available demonstration anywhere in pharmacology that mass is not function, and it is the sentence that should be attached to every body composition claim made for this mechanism.
Step three, the 2026 combination trial, which is the largest dataset on this molecule. 507 adults with obesity (BMI ≥30, or ≥27 with a complication, excluding diabetes) randomized across nine arms: placebo, bimagrumab 10 or 30 mg/kg intravenously every 12 weeks, semaglutide 1.0 or 2.4 mg weekly, and combinations, for 48 weeks with an open-label extension to week 72. Least-squares mean weight change at week 48: −9.3 kg for bimagrumab 30 mg/kg, −14.2 kg for semaglutide 2.4 mg, −17.8 kg for the high-dose combination, against −3.3 kg for placebo, all P<0.001 Heymsfield 2026.
Step four, the meta-analysis, which is where the cost appears. Four randomized trials, 268 participants. Against placebo: total weight −4.85 kg (95% CI −6.82 to −2.88), fat mass −4.72 kg, HbA1c −0.13%, lean mass +1.66 kg. And then: LDL up 0.47 mmol/L (95% CI 0.03 to 0.91), discontinuation RR 5.75, muscle spasms RR 10.44, diarrhea RR 4.91 Shao 2026.
The obstacles. (1) The functional endpoint has been tested once, in a disease population, and it failed Amato 2021. (2) Pooled across trials the weight effect (−4.85 kg) is much smaller than the single phase 2 headline (−5.9 kg in one 37-person arm), and the pooled HbA1c effect (−0.13%) is a fraction of that trial's −0.76 points Shao 2026Heymsfield 2021. (3) It is intravenous and investigational; there is no legitimate supply. (4) No trial has run past 72 weeks Heymsfield 2026.
Bimagrumab pharmacokinetics — how much of it actually gets in
The card says weeks, monoclonal antibody, and that is right. What matters here is why an antibody behaves that way, because it makes this molecule unlike everything else in the Vault.
Nothing metabolizes it in the ordinary sense. A 150-kilodalton IgG is far too large for glomerular filtration, so there is no renal clearance route; it is not a cytochrome substrate, so there is no hepatic oxidation and no CYP interaction list. It is cleared by proteolysis after uptake into cells of the reticuloendothelial system — broken down to amino acids like any other protein. The reason that takes weeks rather than hours is the neonatal Fc receptor: FcRn binds IgG in the acidified endosome and recycles it back to the cell surface instead of routing it to the lysosome. That salvage pathway is the entire explanation for an antibody half-life.
The second clearance route is the target itself. Antibody bound to its receptor is internalized with it, which means clearance is faster when receptor occupancy is low and slows as the target saturates — target-mediated disposition. Practically: exposure rises more than proportionally with dose at the bottom of the range and behaves linearly once the receptor pool is saturated.
The dosing intervals are the evidence. The phase 2 trial dosed 10 mg/kg intravenously every 4 weeks Heymsfield 2021; the 2026 trial dosed 10 or 30 mg/kg every 12 weeks Heymsfield 2026. A drug given quarterly and still producing a 9.3 kg weight difference at 48 weeks has an effective residence measured in weeks to months. Reaching steady state at that half-life takes several dosing intervals, so the first three months of any course are the drug arriving, not the drug working.
Oral is not a possibility and it is worth being explicit. A 150 kDa glycoprotein is digested to peptides by gastric and pancreatic proteases and cannot cross the intestinal epithelium intact. There is no subcutaneous formulation in the published trials either — both used the intravenous route Heymsfield 2021Heymsfield 2026, which is the single most practical fact about availability. Anything sold outside a trial under this name in a small vial for subcutaneous injection is not a 150 kDa human monoclonal antibody, because that is not how antibodies are supplied or dosed.
What would have to be true, and how you would know it was not
Three predictions. The first is favorable, the second is the measured cost, and the third is the one that decides whether the mechanism is worth anything to a healthy person.
1. HbA1c should fall, and by less than the first trial suggested. The phase 2 result was −0.76 percentage points in 37 people with diabetes Heymsfield 2021; pooling four trials gives −0.13% Shao 2026. Prediction: in a population without diabetes, the HbA1c movement is at the pooled end or smaller, and fasting insulin is the more sensitive early marker because added muscle changes glucose disposal before it changes glycated hemoglobin. The falsifier is a repeat of the 0.76-point effect outside a diabetic population.
2. LDL should rise, and this is the measured cost of the mechanism. The meta-analysis found LDL up 0.47 mmol/L (95% CI 0.03 to 0.91) against placebo Shao 2026 — roughly 18 mg/dL, in a population whose fat mass was falling, which is the direction lipids normally improve. Prediction: a lipid panel and an ApoB at baseline and at 12 weeks rise despite visible body composition improvement. ApoB is the marker to use, because a falling-fat, rising-LDL pattern is exactly the situation in which LDL-C and particle number can disagree.
3. Against the mechanism: strength should not track lean mass. This is the prediction the trial history already supports. Two years of treatment in a muscle disease produced progressive deterioration in 6-minute walk distance in every group Amato 2021. Prediction: in a healthy trained person, measured lean mass rises while a one-repetition maximum and a grip strength measurement move by no more than a matched training block would explain. If strength does rise in proportion, that is genuinely new information and it contradicts the only functional dataset that exists. Either result is worth having, and the instruments are a dynamometer and a scan.
What nobody has tested yet
Four questions the trials leave open.
Whether the added tissue is contractile. The IBM extension measured walking distance and found deterioration Amato 2021; no trial has paired a body composition scan with a force measurement and a muscle biopsy in the same participants. Fiber type, capillary density and specific force per cross-sectional area are the measurements that would settle it, and none of them is exotic.
Why LDL rises. The meta-analysis reports the effect Shao 2026; nothing explains it. ActRII ligands have roles in hepatic and lipoprotein biology, so a receptor-level blockade could plausibly act on lipoprotein production rather than on adiposity. It has not been investigated, and it is the finding most likely to matter over years.
Whether the combination preserves the lean mass that matters clinically. The 2026 trial's rationale is that an incretin's weight loss includes lean tissue and this mechanism could offset it Heymsfield 2026. The trial reported weight, not muscle function. Whether a combination arm ends up stronger, not merely heavier in lean compartment, is unmeasured.
What happens to bone. The ligands blocked here have established roles in bone as well as muscle Rodgers 2022. No published bimagrumab trial reports bone mineral density or bone turnover markers over 48 to 72 weeks, and those are standard measurements that would have cost nothing to add.
Bimagrumab — its own safety story, not its class's
The adverse effects here are consistent, quantified and mechanism-linked, which is more than most of this catalog can say.
The numbers, pooled. Against placebo: muscle spasms relative risk 10.44 (95% CI 4.23 to 25.75), diarrhea RR 4.91 (2.38 to 10.11), and discontinuation RR 5.75 (1.61 to 20.46) Shao 2026. A tenfold relative risk of muscle spasms is not a footnote — it is the commonest reason people leave these trials, and it makes sense: a drug that alters the growth signaling of skeletal muscle alters excitability alongside it. Acne is the third reported effect Heymsfield 2026.
The LDL rise belongs in the safety section, not only in the predictions. A 0.47 mmol/L increase Shao 2026 in a person treated for a metabolic indication is a meaningful movement in the wrong direction on the marker most tied to cardiovascular outcome, and it happened while fat mass was falling.
The reassuring part, stated fairly. Two years of treatment in a chronically ill population produced a good safety profile with serious adverse events comparable to placebo — 18.6% against 14.5% Amato 2021. That is a genuine long-duration safety signal, and it is the strongest safety dataset any compound in this cohort has.
And the availability problem, which is this compound's actual risk to a reader. Every published trial used intravenous infusion in a clinical setting Heymsfield 2021Heymsfield 2026. There is no approved product and no legitimate route by which a person obtains this outside a trial. A monoclonal antibody cannot be synthesized in a peptide facility — it requires mammalian cell culture, purification and cold chain — so a vial offered under this name at peptide prices is either not the molecule or is not intact, and there is no assay a buyer can run to tell.
Sources read for this page
- Heymsfield SB, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Network Open 2021 · PMID 33439265
- Amato AA, et al. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology 2021 · PMID 33597289
- Heymsfield SB, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine 2026 · PMID 41772149
- Shao C, et al. Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism 2026 · PMID 42530342
- Rodgers BD, Ward CW. Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs. Endocrine Reviews 2022 · PMID 34520530
Bimagrumab — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Bimagrumab — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Bimagrumab moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Bimagrumab in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Bimagrumab
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
Bimagrumab — frequently asked questions
What is Bimagrumab?
Bimagrumab (Anti-activin type II receptor antibody) is a metabolic & fat loss research compound. A monoclonal antibody that blocks the activin type II receptor, preventing myostatin and activin from signaling. Blocking that pathway removes the brake on muscle growth — the result in trials is simultaneous fat loss and lean mass GAIN, which is close to unique and is exactly why it's being studied alongside GLP-1s, where muscle loss is the main criticism.
Is the full Bimagrumab protocol on this page?
The reported research dose is on this page, along with how Bimagrumab works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Bimagrumab?
Bimagrumab has an approximate half-life of Weeks (monoclonal antibody), which is part of what determines how often it's dosed.
What's the evidence behind Bimagrumab?
Current evidence level: Phase 2 human trials. Bimagrumab is offered for research purposes only and is not an approved medicine.
What Bimagrumab is used for
Bimagrumab appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.